AAAAAA

   
Results: 1-25 | 26-33
Results: 1-25/33
OCCULT CYTOMEGALOVIRUS-INFECTION OF MARROW STROMA
Authors: BOECKH M HOY C TOROKSTORB B
Citation: M. Boeckh et al., OCCULT CYTOMEGALOVIRUS-INFECTION OF MARROW STROMA, Clinical infectious diseases, 26(1), 1998, pp. 209-210
QUANTITATION OF CYTOMEGALOVIRUS - METHODOLOGIC ASPECTS AND CLINICAL-APPLICATIONS
Authors: BOECKH M BOIVIN G
Citation: M. Boeckh et G. Boivin, QUANTITATION OF CYTOMEGALOVIRUS - METHODOLOGIC ASPECTS AND CLINICAL-APPLICATIONS, Clinical microbiology reviews, 11(3), 1998, pp. 533
RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND-STUDY OF A CMV GLYCOPROTEIN H-SPECIFIC MONOCLONAL-ANTIBODY (MSL-109) FOR PREVENTION OF CMV INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT)
Authors: BOECKH M BOWDEN RA CHAO NJ STORER B SPIELBERGER R TIERNEY DK HAWKINS G CUNNINGHAM T LEVITT D ZAIA JA
Citation: M. Boeckh et al., RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND-STUDY OF A CMV GLYCOPROTEIN H-SPECIFIC MONOCLONAL-ANTIBODY (MSL-109) FOR PREVENTION OF CMV INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT), Bone marrow transplantation, 21, 1998, pp. 477-477
EFFECT OF HIGH-DOSE ACYCLOVIR ON SURVIVAL IN ALLOGENEIC MARROW TRANSPLANT RECIPIENTS WHO RECEIVED GANCICLOVIR AT ENGRAFTMENT OR FOR CYTOMEGALOVIRUS PP65 ANTIGENEMIA
Authors: BOECKH M GOOLEY TA BOWDEN RA
Citation: M. Boeckh et al., EFFECT OF HIGH-DOSE ACYCLOVIR ON SURVIVAL IN ALLOGENEIC MARROW TRANSPLANT RECIPIENTS WHO RECEIVED GANCICLOVIR AT ENGRAFTMENT OR FOR CYTOMEGALOVIRUS PP65 ANTIGENEMIA, The Journal of infectious diseases, 178(4), 1998, pp. 1153-1157
CYTOMEGALOVIRUS DISEASE OCCURRING BEFORE ENGRAFTMENT IN MARROW TRANSPLANT RECIPIENTS
Authors: LIMAYE AP BOWDEN RA MYERSON D BOECKH M
Citation: Ap. Limaye et al., CYTOMEGALOVIRUS DISEASE OCCURRING BEFORE ENGRAFTMENT IN MARROW TRANSPLANT RECIPIENTS, Clinical infectious diseases, 24(5), 1997, pp. 830-835
PLASMA POLYMERASE CHAIN-REACTION FOR CYTOMEGALOVIRUS DNA AFTER ALLOGENEIC MARROW TRANSPLANTATION - COMPARISON WITH POLYMERASE CHAIN-REACTION USING PERIPHERAL-BLOOD LEUKOCYTES, PP65 ANTIGENEMIA, AND VIRAL CULTURE
Authors: BOECKH M GALLEZHAWKINS GM MYERSON D ZAIA JA BOWDEN RA
Citation: M. Boeckh et al., PLASMA POLYMERASE CHAIN-REACTION FOR CYTOMEGALOVIRUS DNA AFTER ALLOGENEIC MARROW TRANSPLANTATION - COMPARISON WITH POLYMERASE CHAIN-REACTION USING PERIPHERAL-BLOOD LEUKOCYTES, PP65 ANTIGENEMIA, AND VIRAL CULTURE, Transplantation, 64(1), 1997, pp. 108-113
IDIOPATHIC-PNEUMONIA-SYNDROME - CHANGING SPECTRUM OF LUNG INJURY AFTER MARROW TRANSPLANTATION
Authors: KANTROW SP HACKMAN RC BOECKH M MYERSON D CRAWFORD SW
Citation: Sp. Kantrow et al., IDIOPATHIC-PNEUMONIA-SYNDROME - CHANGING SPECTRUM OF LUNG INJURY AFTER MARROW TRANSPLANTATION, Transplantation, 63(8), 1997, pp. 1079-1086
ADENOVIRUS NEPHRITIS - A SPORADIC AND USUALLY UNDIAGNOSED CAUSE OF RENAL-FAILURE IN MARROW TRANSPLANT PATIENTS
Authors: HACKMAN RC BOECKH M ZAGER D BRUNO B
Citation: Rc. Hackman et al., ADENOVIRUS NEPHRITIS - A SPORADIC AND USUALLY UNDIAGNOSED CAUSE OF RENAL-FAILURE IN MARROW TRANSPLANT PATIENTS, Laboratory investigation, 76(1), 1997, pp. 811-811
CIRCULATING CYTOMEGALOVIRUS(CMV)-INFECTED ENDOTHELIAL-CELLS IN MARROWTRANSPLANT PATIENTS WITH CMV DISEASE AND CMV INFECTION
Authors: SALZBERGER B MYERSON D BOECKH M
Citation: B. Salzberger et al., CIRCULATING CYTOMEGALOVIRUS(CMV)-INFECTED ENDOTHELIAL-CELLS IN MARROWTRANSPLANT PATIENTS WITH CMV DISEASE AND CMV INFECTION, The Journal of infectious diseases, 176(3), 1997, pp. 778-781
NEUTROPENIA IN ALLOGENEIC MARROW TRANSPLANT RECIPIENTS RECEIVING GANCICLOVIR FOR PREVENTION OF CYTOMEGALOVIRUS DISEASE - RISK-FACTORS AND OUTCOME
Authors: SALZBERGER B BOWDEN RA HACKMAN RC DAVIS C BOECKH M
Citation: B. Salzberger et al., NEUTROPENIA IN ALLOGENEIC MARROW TRANSPLANT RECIPIENTS RECEIVING GANCICLOVIR FOR PREVENTION OF CYTOMEGALOVIRUS DISEASE - RISK-FACTORS AND OUTCOME, Blood, 90(6), 1997, pp. 2502-2508
ASSOCIATION OF SPECIFIC CYTOMEGALOVIRUS GENOTYPES WITH DEATH FROM MYELOSUPPRESSION AFTER MARROW TRANSPLANTATION
Authors: TOROKSTORB B BOECKH M HOY C LEISENRING W MYERSON D GOOLEY T
Citation: B. Torokstorb et al., ASSOCIATION OF SPECIFIC CYTOMEGALOVIRUS GENOTYPES WITH DEATH FROM MYELOSUPPRESSION AFTER MARROW TRANSPLANTATION, Blood, 90(5), 1997, pp. 2097-2102
NEUTROPHIL COLLECTION FROM COMMUNITY APHERESIS DONORS AFTER GRANULOCYTE-COLONY-STIMULATING FACTOR AND DEXAMETHASONE STIMULATION - FEASIBILITY AND EFFICACY
Authors: PRICE TH BOWDEN RA BOECKH M LILES WC LLEWELLYN C FULLER F DALE DC
Citation: Th. Price et al., NEUTROPHIL COLLECTION FROM COMMUNITY APHERESIS DONORS AFTER GRANULOCYTE-COLONY-STIMULATING FACTOR AND DEXAMETHASONE STIMULATION - FEASIBILITY AND EFFICACY, Blood, 90(10), 1997, pp. 3327-3327
ADENOVIRUS INFECTIONS IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION
Authors: BRUNO B BOECKH M DAVIS C GOOLEY T HACKMAN RC
Citation: B. Bruno et al., ADENOVIRUS INFECTIONS IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION, Blood, 90(10), 1997, pp. 1867-1867
PHASE I II STUDY OF GRANULOCYTE TRANSFUSIONS FROM G-CSF-STIMULATED UNRELATED DONORS FOR TREATMENT INFECTIONS IN NEUTROPENIC BLOOD AND MARROW TRANSPLANT (BMT) PATIENTS/
Authors: BOWDEN R PRICE T BOECKH M LILES C CAYS M GALE D
Citation: R. Bowden et al., PHASE I II STUDY OF GRANULOCYTE TRANSFUSIONS FROM G-CSF-STIMULATED UNRELATED DONORS FOR TREATMENT INFECTIONS IN NEUTROPENIC BLOOD AND MARROW TRANSPLANT (BMT) PATIENTS/, Blood, 90(10), 1997, pp. 1930-1930
CYCLOSPORINE OR CYCLOSPORINE PLUS METHYLPREDNISOLONE FOR PROPHYLAXIS OF GRAFT-VERSUS-HOST DISEASE - A PROSPECTIVE, RANDOMIZED TRIAL
Authors: DEEG HJ LIN DY LEISENRING W BOECKH M ANASETTI C APPELBAUM FR CHAUNCEY TR DONEY K FLOWERS M MARTIN P NASH R SCHOCH G SULLIVAN KM WITHERSPOON RP STORB R
Citation: Hj. Deeg et al., CYCLOSPORINE OR CYCLOSPORINE PLUS METHYLPREDNISOLONE FOR PROPHYLAXIS OF GRAFT-VERSUS-HOST DISEASE - A PROSPECTIVE, RANDOMIZED TRIAL, Blood, 89(10), 1997, pp. 3880-3887
HEPATIC MUCORMYCOSIS IN A BONE-MARROW TRANSPLANT RECIPIENT WHO INGESTED NATUROPATHIC MEDICINE
Authors: OLIVER MR VANVOORHIS WC BOECKH M MATTSON D BOWDEN RA
Citation: Mr. Oliver et al., HEPATIC MUCORMYCOSIS IN A BONE-MARROW TRANSPLANT RECIPIENT WHO INGESTED NATUROPATHIC MEDICINE, Clinical infectious diseases, 22(3), 1996, pp. 521-524
EVALUATION OF CMV BRITE KIT FOR DETECTION OF CYTOMEGALOVIRUS PP65 ANTIGENEMIA IN PERIPHERAL-BLOOD LEUKOCYTES BY IMMUNOFLUORESCENCE
Authors: LANDRY ML FERGUSON D STEVENSAYERS T DEJONGE MWA BOECKH M
Citation: Ml. Landry et al., EVALUATION OF CMV BRITE KIT FOR DETECTION OF CYTOMEGALOVIRUS PP65 ANTIGENEMIA IN PERIPHERAL-BLOOD LEUKOCYTES BY IMMUNOFLUORESCENCE, Journal of clinical microbiology, 34(5), 1996, pp. 1337-1339
HIGH-LEVEL SENSITIVITY OF QUANTITATIVE PP65 CYTOMEGALOVIRUS (CMV) ANTIGENEMIA ASSAY FOR DIAGNOSIS OF CMV DISEASE IN AIDS PATIENTS AND FOLLOW-UP (VOL 34, PG 458, 1996)
Authors: BEK B BOECKH M LEPENIES J BIENIEK B ARASTEH K HEISE W DEPPERMANN KM BORNHOFT G STOFFLERMEILICKE M SCHULLER I HOFFKEN G
Citation: B. Bek et al., HIGH-LEVEL SENSITIVITY OF QUANTITATIVE PP65 CYTOMEGALOVIRUS (CMV) ANTIGENEMIA ASSAY FOR DIAGNOSIS OF CMV DISEASE IN AIDS PATIENTS AND FOLLOW-UP (VOL 34, PG 458, 1996), Journal of clinical microbiology, 34(5), 1996, pp. 1350-1350
HIGH-LEVEL SENSITIVITY OF QUANTITATIVE PP65 CYTOMEGALOVIRUS (CMV) ANTIGENEMIA ASSAY FOR DIAGNOSIS OF CMV DISEASE IN AIDS PATIENTS AND FOLLOW-UP
Authors: BEK B BOECKH M LEPENIES J BIENIEK B ARASTEH K HEISE W DEPPERMANN KM BORNHOFT G STOFFLERMEILICKE M SCHULLER I HOFFKEN G
Citation: B. Bek et al., HIGH-LEVEL SENSITIVITY OF QUANTITATIVE PP65 CYTOMEGALOVIRUS (CMV) ANTIGENEMIA ASSAY FOR DIAGNOSIS OF CMV DISEASE IN AIDS PATIENTS AND FOLLOW-UP, Journal of clinical microbiology, 34(2), 1996, pp. 457-459
INTEREST OF QUANTITATIVE PP65 CYTOMEGALOVIRUS ANTIGENEMIA ASSAY FOR HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE PATIENTS - REPLY
Authors: BOECKH M BEK B LEPENIES J HOFFKEN G
Citation: M. Boeckh et al., INTEREST OF QUANTITATIVE PP65 CYTOMEGALOVIRUS ANTIGENEMIA ASSAY FOR HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE PATIENTS - REPLY, Journal of clinical microbiology, 34(12), 1996, pp. 3255-3256
CYTOMEGALOVIRUS PP65 ANTIGENEMIA AFTER AUTOLOGOUS MARROW AND PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION
Authors: BOECKH M STEVENSAYERS T BOWDEN RA
Citation: M. Boeckh et al., CYTOMEGALOVIRUS PP65 ANTIGENEMIA AFTER AUTOLOGOUS MARROW AND PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION, The Journal of infectious diseases, 174(5), 1996, pp. 907-912
MARROW ALLOGRAFT FAILURE IS ASSOCIATED WITH SPECIFIC CYTOMEGALOVIRUS (CMV) GENOTYPES
Authors: HOV C GOOLEY T LEISENRING W BOECKH M MYERSON D TOROKSTORB B
Citation: C. Hov et al., MARROW ALLOGRAFT FAILURE IS ASSOCIATED WITH SPECIFIC CYTOMEGALOVIRUS (CMV) GENOTYPES, Blood, 88(10), 1996, pp. 1193-1193
INCREASED RISK OF LATE CMV INFECTION AND DISEASE IN ALLOGENEIC MARROWTRANSPLANT RECIPIENTS AFTER GANCICLOVIR PROPHYLAXIS IS DUE TO A LACK OF CMV-SPECIFIC T-CELL RESPONSES
Authors: BOECKH M RIDDELL SR CUNNINGHAM T MYERSON D FLOWERS M BOWDEN RA
Citation: M. Boeckh et al., INCREASED RISK OF LATE CMV INFECTION AND DISEASE IN ALLOGENEIC MARROWTRANSPLANT RECIPIENTS AFTER GANCICLOVIR PROPHYLAXIS IS DUE TO A LACK OF CMV-SPECIFIC T-CELL RESPONSES, Blood, 88(10), 1996, pp. 1195-1195
ADENOVIRUS NEPHRITIS - A NEWLY DESCRIBED CLINICAL-PATHOLOGICAL ENTITYIN BONE-MARROW TRANSPLANTATION
Authors: BRUNO B BOECKH M ZAGER D HACKMAN RC
Citation: B. Bruno et al., ADENOVIRUS NEPHRITIS - A NEWLY DESCRIBED CLINICAL-PATHOLOGICAL ENTITYIN BONE-MARROW TRANSPLANTATION, Blood, 88(10), 1996, pp. 1200-1200
NEUTROPENIA IN ALLOGENEIC MARROW TRANSPLANT RECIPIENTS RECEIVING GANCICLOVIR FOR PREVENTION OF CMV-DISEASE - RISK-FACTORS AND OUTCOME
Authors: SALZBERGER B BOWDEN RA HACKMAN RC DAVIS C BOECKH M
Citation: B. Salzberger et al., NEUTROPENIA IN ALLOGENEIC MARROW TRANSPLANT RECIPIENTS RECEIVING GANCICLOVIR FOR PREVENTION OF CMV-DISEASE - RISK-FACTORS AND OUTCOME, Blood, 88(10), 1996, pp. 1682-1682
Risultati: 1-25 | 26-33